ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

Summary

This is a Phase 1, open-label, single center, non-randomized study to evaluate the absorption, distribution, metabolism and excretion (ADME) of an oral solution of radiolabeled Ibrexafungerp following repeat administration in healthy male subjects. All subjects will undergo preliminary screening procedures, will remain the clinical unit for approximately 26 days and will receive radiolabeled Ibrexafungerp, orally for 3 days.

Timeline

Start

2022-12-14

Primary completion

2023-01-28

Completion

2023-01-28

Drugs

Indications